1 / 109

Adénopathies métastatiques

Adénopathies métastatiques. Jean-Pascal Machiels Cliniques Universitaires Saint-Luc Université Catholique de Louvain. Adénopathie cervicale. Mr H., 62 ans Tuméfaction cervicale droite. Anamnèse. AP: Consommation tabagique>40 UAP

Download Presentation

Adénopathies métastatiques

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Adénopathies métastatiques Jean-Pascal Machiels Cliniques Universitaires Saint-Luc Université Catholique de Louvain

  2. Adénopathie cervicale • Mr H., 62 ans • Tuméfaction cervicale droite

  3. Anamnèse • AP: • Consommation tabagique>40 UAP • Infarctus mésentérique avec péritonite traités chirurgicalement • Ulcère gastrique • Coma éthylique

  4. Depuis 5 mois: masse cervicale gauche indolore • Pas d’AEG ou de symptômes B • Signale des lourdeurs épigastriques • Pas de traitement au domicile

  5. Examen clinique • Paramètre nx • Souffle syst. 2/6 au FM • Crépitants base pulm. gauche • Abdomen: sp • Masse mal délimitée indolore non inflammatoire au niveau cervical droit

  6. Biologie • Normale • CEA=8.3 ng/ml (N<3)

  7. RX thorax • normale

  8. Echographie cervicale • Nombreux ggl le long du SCM (dont certains>2 cm d’axe). Un d’entre eux semble infiltrer le muscle. Certains ggl sont partiellement nécrotiques.

  9. Scanner thoraco-abdominal • Présence de ggl médiastinaux. • Au niveau abdo: thrombose de l’artère mésentérique sup avec suppléance via l’arcade de Riolan. Présence de ggl rétropéritonéaux, mésentériques, inguinaux et iliaques, infracm.

  10. PET Scanner • Adénopathies hypermétaboliques cervicales gauches

  11. Fibroscopie ORL • Sp à part une compression extrinsèque du pharynx au niveau de sa paroi postérieure à droite

  12. Fibroscopie normale • Gastroscopie normale

  13. Quelle mise au point complémentaire?

  14. Exérèse chirurgicale • Carcinome peu différencié d’origine indéterminée au niveau cervical droite

  15. Evaluation and Management of the Patient with a Neck Mass

  16. General Considerations • Patient age • Pediatric (0 – 15 years): 90% benign • Young adult (16 – 40 years): similar to pediatric • Late adult (>40 years): “rule of 80s” • Location • Congenital masses: consistent in location • Metastatic masses: key to primary lesion

  17. Differential Diagnosis

  18. Diagnostic Steps • History • Developmental time course • Associated symptoms (dysphagia, otalgia, voice) • Personal habits (tobacco, alcohol) • Previous irradiation or surgery • Physical Examination • Complete head and neck exam (visualize & palpate) • Emphasis on location, mobility and consistency

  19. Empirical Antibiotics • Inflammatory mass suspected • Two week trial of antibiotics • Follow-up for further investigation

  20. Diagnostic Tests • Fine needle aspiration biopsy (FNAB) • Computed tomography (CT) • Magnetic resonance imaging (MRI) • Ultrasonography • Radionucleotide scanning

  21. Fine Needle Aspiration Biopsy • Standard of diagnosis • Indications • Any neck mass that is not an obvious abscess • Persistence after a 2 week course of antibiotics • Small gauge needle • Reduces bleeding • Seeding of tumor – not a concern • No contraindications (vascular ?)

  22. Fine Needle Aspiration Biopsy

  23. Computed Tomography • Distinguish cystic from solid • Extent of lesion • Vascularity (with contrast) • Detection of unknown primary (metastatic) • Pathologic node (lucent, >1.5cm, loss of shape) • Avoid contrast in thyroid lesions

  24. Magnetic Resonance Imaging • Similar information as CT • Better for upper neck and skull base • Vascular delineation with infusion

  25. Ultrasonography • Less important now with FNAB • Solid versus cystic masses • Congenital cysts from solid nodes/tumors • Noninvasive (pediatric)

  26. Radionucleotide Scanning • Salivary and thyroid masses • Location – glandular versus extra-glandular • Functional information • FNAB now preferred for for thyroid nodules • Solitary nodules • Multinodular goiter with new increasing nodule • Hashimoto’s with new nodule

  27. Thyroid mass Lymphoma Salivary tumors Lipoma Carotid body and glomus tumors Neurogenic tumors Primary Tumors

  28. Lymphoma • More common in children and young adults • Up to 80% of children with Hodgkin’s have a neck mass • Signs and symptoms • Lateral neck mass only (discrete, rubbery, nontender) • Fever • Hepatosplenomegaly • Diffuse adenopathy

  29. Lymphoma • FNAB – first line diagnostic test • If suggestive of lymphoma – open biopsy • Full workup – CT scans of chest, abdomen, head and neck; bone marrow biopsy

  30. Salivary Gland Tumors • Enlarging mass anterior/inferior to ear or at the mandible angle is suspect • Benign • Asymptomatic except for mass • Malignant • Rapid growth, skin fixation, cranial nerve palsies

  31. Salivary Gland Tumors

  32. Carotid Body Tumor • Rare in children • Pulsatile, compressible mass • Mobile medial/lateral not superior/inferior • Clinical diagnosis, confirmed by angiogram or CT • No biopsy !!! • Treatment • Irradiation or close observation in the elderly • Surgical resection for small tumors in young patients • Hypotensive anesthesia • Preoperative measurement of catecholamines

  33. Carotid Body Tumor

  34. Lipoma • Soft, ill-defined mass • Usually >35 years of age • Asymptomatic • Clinical diagnosis – confirmed by excision

  35. Lipoma

  36. Congenital and Developmental Mass • Epidermal and sebaceous cysts • Branchial cleft cysts • Thyroglossal duct cyst • Vascular tumors

  37. Epidermal and Sebaceous Cysts

  38. Branchial Cleft Cysts • Most common as smooth, fluctuant mass underlying the SCM • Skin erythema and tenderness if infected • Treatment • Initial control of infection • Surgical excision, including tract • May necessitate a total parotidectomy (1st cleft)

  39. Branchial Cleft Cysts

  40. Inflammatory Disorders • Lymphadenitis • Granulomatous lymphadenitis

  41. Our Patient • squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site

  42. Incidence Author # pts % Jungehulsing 723 3.7 Lefebvre 8,500 2.2 Martin 3,896 5.6 Randall 829 4.0 Richard 5,137 3.3 Jungehulsing, 2000 Lefebvre, 1990 Martin, 1944 Randall, 2000 Richard, 1977

  43. 5% 12% 60% 22% 11% 13% Diagnosis 7 series (n=797) Bataini, 1987 Coker, 1977 Jesse, 1972 Marcial-Vega, 1990 Maulard, 1992 Wang, 1990

  44. Metastasis Location according to Various Primary Lesions

  45. Nodal Mass Workup in the Adult • Panendoscopy • FNAB positive with no primary on repeat exam • FNAB equivocal/negative in high risk patient • Directed Biopsy • All suspicious mucosal lesions • Areas of concern on CT/MRI • None observed – nasopharynx, tonsil (ipsilateral tonsillectomy for jugulodigastric nodes), base of tongue and piriforms • Synchronous primaries (10 to 20%)

  46. Nodal Mass Workup in the Adult • Open excisional biopsy • Only if complete workup negative including FNA • Occurs in ~5% of patients • Be prepared for a complete neck dissection • Frozen section results (complete node excision) • Inflammatory or granulomatous – culture • Lymphoma or adenocarcinoma – close wound

  47. Biopsy-proven primary 43% Unknown Primary Clinical ex. CT/(NMR) 5% Unknown Primary 3% PET-guided biopsy Tonsillectomy Diagnosis 130 suspected H&N unknown primaries Mendenhall, 1998

  48. TNM/AJCC 1997 Staging • N0: no regional node metastasis • Nx: regional nodes cannot be assessed • N1: single ipsilateral node, ≤ 3 cm • N2a: single ipsilateral node, > 3 cm and ≤ 6 cm • N2b: multiple ipsilateral nodes, ≤ 6 cm • N2c: controlateral or bilateral nodes, ≤ 6 cm • N3: node > 6 cm AJCC, 1997

  49. Treatment: survival 5 year survival median (min-max) All patients (23 series, n=2,167) 38% (15-65) N stage (n=932) N1 58% (19-90) N2a 41% (15-87) N2b 40% (15-63) N2c-N3 21% (0-62) Treatment Surgery (n=439) 66% (65-86) Surgery + RxTh (n=856) 50% (28-63) RxTh ± excision (n=553) 37% (16-74)

More Related